Home Page: Cancer Treatment Reviews

Previous slide

Pause slide

Next slide

SARS-CoV-2 and cancer: Are they really partners in crime?

Peter A. van Dam, Manon Huizing, Gino Mestach, Stazie Dierckxsens, Wiebren Tjalma, Xuan Bich Trinh, Kostantinos Papadimitriou, Sevilay Altintas, Jan Vermorken, Christof Vulsteke, Annelies Janssens, Zwi Berneman, Hans Prenen, Leander Meuris, Wim Vanden Berghe, Evelien Smits, Marc Peeters

DOI: https://doi.org/10.1016/j.ctrv.2020.102068

Vol. 89

Published online: July 10, 2020

Open Access

Full-Text HTML PDF

Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics

Johny E. Fares, Paul El Tomb, Lana E. Khalil, Rula W. Atwani, Hiba A. Moukadem, Ahmad Awada, Nagi S. El Saghir

DOI: https://doi.org/10.1016/j.ctrv.2020.102066

Vol. 89

Published online: June 29, 2020

Full-Text HTML PDF

Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities

Elisa Fontana, Hendrik-Tobias Arkenau

DOI: https://doi.org/10.1016/j.ctrv.2020.102047

Vol. 88

Published online: June 10, 2020

Full-Text HTML PDF

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)

Florian Slimano, Amandine Baudouin, Jérémie Zerbit, Anne Toulemonde-Deldicque, Audrey Thomas-Schoemann, Régine Chevrier, Mikaël Daouphars, Isabelle Madelaine, Bertrand Pourroy, Jean-François Tournamille, Alain Astier, Florence Ranchon, Jean-Louis Cazin, Christophe Bardin, Catherine Rioufol

DOI: https://doi.org/10.1016/j.ctrv.2020.102063

Vol. 88

Published online: June 22, 2020

Full-Text HTML PDF Supplemental Materials

Cancer and COVID-19: Unmasking their ties

A. Addeo, A. Friedlaender

DOI: https://doi.org/10.1016/j.ctrv.2020.102041

Vol. 88

Published online: June 3, 2020

Full-Text HTML PDF

MYC as a Target for Cancer Treatment

Michael J Duffy, Shane O'Grady, Minhong Tang, John Crown

DOI: https://doi.org/10.1016/j.ctrv.2021.102154

Publication stage: In Press Journal Pre-Proof

Open Access

Preview Full-Text HTML PDF

Diagnostics, Therapeutics and RET Inhibitor Resistance for RET Fusion–Positive Non-Small Cell Lung Cancers and Future Perspectives

Chang Lu, Qing Zhou

DOI: https://doi.org/10.1016/j.ctrv.2021.102153

Publication stage: In Press Journal Pre-Proof

Open Access

Preview Full-Text HTML PDF

View More Articles in Press

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

Josep Garcia, Herbert I. Hurwitz, Alan B. Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot

DOI: https://doi.org/10.1016/j.ctrv.2020.102017

Vol. 86

Published online: March 26, 2020

Open Access

Full-Text HTML PDF

How did lomustine become standard of care in recurrent glioblastoma?

Michael Weller, Emilie Le Rhun

DOI: https://doi.org/10.1016/j.ctrv.2020.102029

Vol. 87

Published online: May 4, 2020

Open Access

Full-Text HTML PDF

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

Mario Sznol, Michael A. Postow, Marianne J. Davies, Anna C. Pavlick, Elizabeth R. Plimack, Montaser Shaheen, Colleen Veloski, Caroline Robert

DOI: https://doi.org/10.1016/j.ctrv.2017.06.002

Vol. 58

Published online: June 22, 2017

Open Access

Full-Text HTML PDF Supplemental Materials

PARP inhibitors in ovarian cancer

Elisena Franzese, Sara Centonze, Anna Diana, Francesca Carlino, Luigi Pio Guerrera, Marilena Di Napoli, Ferdinando De Vita, Sandro Pignata, Fortunato Ciardiello, Michele Orditura

DOI: https://doi.org/10.1016/j.ctrv.2018.12.002

Vol. 73

Published online: December 4, 2018

Open Access

Full-Text HTML PDF

Cancer and COVID-19: Unmasking their ties

A. Addeo, A. Friedlaender

DOI: https://doi.org/10.1016/j.ctrv.2020.102041

Vol. 88

Published online: June 3, 2020

Full-Text HTML PDF

January 2021
Volume 92

January 2021

Volume 92

Cancer Treatment Reviews (Incorporating Evidence-based Oncology) is an international review journal that will keep both the clinician and researcher abreast of modern concepts and developments in cancer treatment research through the publication of state of the art, authoritative reviews; evidence-based reviews (using a priori defined selection process to identify key articles from the literature and reviewing them in the form of a structured abstract, evidence summary and commentary); and systematic reviews.

Issue Highlights

Sarcomas: Immune biomarker expression and checkpoint inhibitor trials

Newly diagnosed ovarian cancer: Which first-line treatment?

National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study

SARS-CoV-2 and cancer: Are they really partners in crime?

Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics

Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities

Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)

Cancer and COVID-19: Unmasking their ties

MYC as a Target for Cancer Treatment

Diagnostics, Therapeutics and RET Inhibitor Resistance for RET Fusion–Positive Non-Small Cell Lung Cancers and Future Perspectives

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

How did lomustine become standard of care in recurrent glioblastoma?

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

PARP inhibitors in ovarian cancer

Cancer and COVID-19: Unmasking their ties

2020 Cited articles

Current Issue

List of Issues

Journal Metrics

Journal Access

About Cancer Treatment Reviews

Journal Insights